CN104906145A - Medical application of paecilomyces hepiali mutant strain PH40 in treating diabetes - Google Patents
Medical application of paecilomyces hepiali mutant strain PH40 in treating diabetes Download PDFInfo
- Publication number
- CN104906145A CN104906145A CN201510280983.3A CN201510280983A CN104906145A CN 104906145 A CN104906145 A CN 104906145A CN 201510280983 A CN201510280983 A CN 201510280983A CN 104906145 A CN104906145 A CN 104906145A
- Authority
- CN
- China
- Prior art keywords
- peacilomyce hepiahi
- strain
- mycopowder
- mutagenic strain
- rat
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The invention discloses medical application of a paecilomyces hepiali mutant strain PH40 in treating diabetes. The obvious medical effect is achieved. The paecilomyces hepiali mutant strain PH40 is obtained through mutation screening with a paecilomyces hepialid strain (RCEF1429) as an original strain. The paecilomyces hepiali mutant strain PH40 was preserved in China Center for Type Culture Collection in December 26, 2014, and the preservation number is CCTCC M2014670.
Description
Technical field
The invention discloses the medical application of peacilomyce hepiahi mutagenic strain PH40 in treatment diabetes, belong to Chinese medicine and health product technology field.
Background technology
The metabolic disease of diabetes to be one group with hyperglycemia be feature, long-standing hyperglycemia, causes patient various tissue, particularly eye, kidney, heart, blood vessel, neural chronic lesion, dysfunction.International Tang Bing alliance statistics, the nineties in 20th century, global diabetics about 100,000,000 people, by 2007, this numeral rose to 2.46 hundred million, expected 2025, the puzzlement that the whole world will have 3.8 hundred million people by diabetes.China is diabetes second big country being only second to India, and according to health ministry investigation display, China's about newly-increased diabetics 3000 every day is routine, every year about newly-increased 1,200,000 diabeticss, and the direct medical care expenses of diabetes increases rapidly with the ratio of average annual 19.90%.The ever-increasing prevalence of diabetes and financial burden have caused the extensive concern of the whole society.
Current Remedies for diabetes is mainly divided into oral drugs and insulin injection class, and oral drug administration is convenient, but with larger side effect, the simultaneously commercially available at present preventive effect of antidiabetic medicine to diabetic complication is weak, and can not thoroughly cure.Insulin injection class medicine is difficult to control, and easily causes insulin resistant, increases the treatment difficulty of disease.
Peacilomyce hepiahi is the endophyte be separated in natural cordyceps, the phorozoon of ubiquitous a kind of Cordyceps in natural cordyceps, its mycelium fermentation thing has pharmacologically active widely, can as the raw material of natural cordyceps effective ingredient and effect, and DEVELOPMENT PROSPECT is wide.
Summary of the invention
The invention discloses the medical application of peacilomyce hepiahi mutagenic strain PH40 in diabetes, there is obvious medical effect.
Peacilomyce hepiahi mutagenic strain PH40 of the present invention is with peacilomyce hepiahi bacterium strain (RCEF1429) for original strain, obtains through mutagenesis screening, in December in 2014 preservation " China typical culture collection center " on the 26th, and called after:
paecilomyces hepidl chenpH40; Peacilomyce hepiahi bacterium strain PH40, preserving number is: CCTCC NO:M 2014670.
Peacilomyce hepiahi mutagenic strain PH40 mycopowder of the present invention is realized by following technical scheme.
A () liquid submerged fermentation method fermenting and producing peacilomyce hepiahi mutagenic strain PH40, collect fermentation liquid, the centrifugal 10min of 5000r/min, collecting precipitation, lyophilizing, obtains peacilomyce hepiahi superior strain mycelium.
B () gets peacilomyce hepiahi mutagenic strain PH40 mycelium, add pharmaceutic adjuvant, prepares peacilomyce hepiahi mutagenic strain PH40 mycopowder preparation.
C () peacilomyce hepiahi mutagenic strain PH40 mycopowder and preparation have anti-diabetic activity.
The present invention adopts high glucose and high fat forage feed to set up type-II diabetes rat model in conjunction with low dose of streptozotocin injecting method, adopts this rat model to prove peacilomyce hepiahi mutagenic strain PH40 anti-diabetic activity.This research belongs to mushroom medicine in Chinese medicine and health product research and development field, for peacilomyce hepiahi high yield mutagenic strain PH
40for the exploitation of the new product of primary raw material provides foundation.
good effect of the present invention is:provide peacilomyce hepiahi mutagenic strain PH40 and prepare the purposes for the treatment of in diabetes medicament, to advanced diabetes nephritis complication, there is good preventive effect.
Detailed description of the invention
In order to technology contents of the present invention can be understood better, describe the present invention below by concrete case study on implementation.
embodiment 1
Utilize liquid submerged fermentation method fermenting and producing peacilomyce hepiahi mutagenic strain PH40, get peacilomyce hepiahi mutagenic strain PH40 fermentation liquid 1L, the centrifugal 10min of 5000r/min, collecting precipitation, vacuum lyophilization, adopts high speed disintegrator to pulverize, crosses 60 mesh sieves, collecting mycopowder, is peacilomyce hepiahi mutagenic strain PH40 mycopowder 1
embodiment 2
Utilize liquid submerged fermentation method fermenting and producing peacilomyce hepiahi mutagenic strain PH40, get peacilomyce hepiahi mutagenic strain PH40 fermentation liquid 1L, spraying dry, collecting mycopowder, is peacilomyce hepiahi mutagenic strain PH40 mycopowder 2.
embodiment 3
Utilize liquid submerged fermentation method fermenting and producing peacilomyce hepiahi mutagenic strain PH40, get peacilomyce hepiahi mutagenic strain PH40 fermentation liquid 1L, the centrifugal 10min of 5000r/min, collecting precipitation, vacuum lyophilization, adopts high speed disintegrator to pulverize, crosses 60 mesh sieves, collecting mycopowder, is peacilomyce hepiahi mutagenic strain PH40 mycopowder 3.
Get mycopowder 3, add the pharmaceutic adjuvant such as sodium bicarbonate, sodium carboxymethyl cellulose, prepare peacilomyce hepiahi mutagenic strain PH40 mycopowder preparation 3.
embodiment 4
The peacilomyce hepiahi mutagenic strain PH40 mycopowder prepared with embodiment 1 ~ 3 for main component, in addition multiple pharmaceutic adjuvant, the tablet prepared, powder, capsule and oral formulations.
below test shows the application of the present invention in anti-diabetic health product:
1, materials and methods
1.1 tested material embodiment 1 mycopowder 1, embodiment 2 mycopowder 2, embodiment 3 preparation 3.
1.2 laboratory animal
Healthy SD male rat 200 is provided, body weight 180-220g by Jilin University's Experimental Animal Center.Be divided into 5 groups at random, often organize 40.
1.3 zoopery room environmentals
Temperature 22 DEG C, humidity 52%.
1.4 dosage choice
The recommended dose of this health-care preparation is adult's (calculating by body weight 60kg) 1.2g, by 12 times of human body recommended amounts, administration is carried out to rat, three groups of tested materials are configured to normal saline the solution that concentration is 0.02g/ml respectively, the administration of modeling rat oral gavage measured indices after 4 weeks, and gastric infusion volume is 2.0ml/kg.Arrange a blank group, replace tested material to carry out administration with normal saline, gavage volume is identical with tested material simultaneously.
1.5 experimental technique
1.5.1 the foundation of type-II diabetes rat model
Healthy SD rat, after adaptability feeds 2 days, high glucose and high fat forage feed is after 2 months, and water 12h is can't help in fasting, the 2%STZ(streptozotocin of low dose of tail vein injection pre-cooling in continuous a week, matching while using), injected dose is 25 mg/kg/d.After injection, 3h gavage is containing 25% glucose 0.8 ml/200g; Normal group injection equal-volume citrate buffer solution (pH4.3).Tail vein blood after 72h, surveys fasting glucose, with blood glucose value >=11.1 mmol/L persons for modeling success.
1.5.2 laboratory animal body weight and change of blood sugar
During rat administration, tail venous blood sampling, surveys blood glucose target before and after its treatment, records body weight change before and after rat treatment simultaneously.
Result shows, peacilomyce hepiahi mutagenic strain PH40 mycopowder and preparation significantly can reduce type-II diabetes rat rapid blood sugar value, there is significance difference opposite sex p<0.01 compared with model group, rat body weight p<0.01 can be significantly improved simultaneously, prove peacilomyce hepiahi PH
40there is good hypoglycemic activity.
on the impact of rat insulin level
Defect of insulin secretion is
one of marked feature of patients with type Ⅰ DM, low insulin secretion causes the disorder of glucose and lipid metabolism in body.Before and after diabetes rat administration, rat tail vein gets blood, adopts plasma insulin change before and after treatment.
Result shows, and compared with model group, peacilomyce hepiahi mutagenic strain PH40 mycopowder and preparation can significantly improve the rear plasma insulin level of rat treatment, and result p<0.005, has significant difference.
rat glycated hemoglobin levels changes
Glycolated hemoglobin is the product that in erythrocyte, hemoglobin is combined with blood glucose, the generation of glycolated hemoglobin is irreversible, and its concentration becomes relevant to blood sugar concentration, in erythrocyte, the concentration of glycolated hemoglobin can reflect the change of blood sugar concentration in patient 8-12 week usually, embodies diabetics to the control situation of blood glucose.After rat administration terminates, heart extracting blood, measures glycated hemoglobin levels in Rat Erythrocytes.
Result shows, and model group rats glycated hemoglobin levels significantly raises, p<0.01; Compared with model group, experimental group rat glycated hemoglobin levels all significantly declines, p<0.01.Illustrate that peacilomyce hepiahi mutagenic strain PH40 mycopowder and preparation control better blood glucose in diabetic rats level.
in rat blood serum, Pyruvate kinase activity detects
Pyruvate kinase is the rate-limiting enzyme decomposed in glucose body, and the change of its activity directly affects the decomposition utilization of body glucose molecule.After rat treatment terminates, heart extracting blood, measures rat blood serum pyruvate kinase content.
Result shows, and model group rats serum pyruvate kinase level significantly declines, p<0.01, and glucose utilization rate declines; Compared with model group, experimental group rat blood serum pyruvate kinase level all significantly rises, p<0.01.Illustrate that peacilomyce hepiahi mutagenic strain PH40 mycopowder and preparation have higher facilitation to diabetes rat serum pyruvate kinase level.
peacilomyce hepiahi superior strain is on the impact of the Nephritis Rats factor
Rat treatment terminates, and heart extracting blood measures rat blood serum uric acid, blood urea nitrogen, serum albumin, total protein levels.
Result shows, compared with model group, experimental group rat blood serum uric acid, blood urea nitrogen, total protein levels significantly decline (p<0.01), albumin level significantly rises (p<0.01), illustrates that peacilomyce hepiahi mutagenic strain PH40 mycopowder and preparation have good preventive and therapeutic action to Diabetic Nephropathy.
to sum up result proves,peacilomyce hepiahi mutagenic strain PH40 mycopowder and preparation have very high antidiabetic effect, have good preventive effect to advanced diabetes nephritis complication.
Claims (3)
1. the medical application of peacilomyce hepiahi mutagenic strain PH40 in preparation treatment diabetes medicament; Described bacterial strain in December in 2014 preservation " China typical culture collection center " on the 26th, called after:
paecilomyces hepidl chenpH40; Peacilomyce hepiahi bacterium strain PH40, preserving number is: CCTCC NO:M 2014670.
2. the preparation method of a peacilomyce hepiahi mutagenic strain PH40 mycopowder, its feature is in the fermentation liquid 1L utilizing peacilomyce hepiahi mutagenic strain PH40 described in claim 1, the centrifugal 10min of 5000r/min, collecting precipitation, vacuum lyophilization, employing high speed disintegrator is pulverized, and crosses 60 mesh sieves, collects mycopowder and get final product.
3. the peacilomyce hepiahi mutagenic strain PH40 mycopowder prepared with claims 2 for main component, in addition multiple pharmaceutic adjuvant, the tablet prepared, powder, capsule and oral formulations.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510280983.3A CN104906145B (en) | 2015-05-28 | 2015-05-28 | Medical application of the Paecilomyces hepiali chen mutagenic strain PH40 in treatment diabetes |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510280983.3A CN104906145B (en) | 2015-05-28 | 2015-05-28 | Medical application of the Paecilomyces hepiali chen mutagenic strain PH40 in treatment diabetes |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN104906145A true CN104906145A (en) | 2015-09-16 |
| CN104906145B CN104906145B (en) | 2019-02-01 |
Family
ID=54075864
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510280983.3A Active CN104906145B (en) | 2015-05-28 | 2015-05-28 | Medical application of the Paecilomyces hepiali chen mutagenic strain PH40 in treatment diabetes |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104906145B (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105853717A (en) * | 2016-04-05 | 2016-08-17 | 上海育生堂科技有限公司 | Chinese patent medicine for treating type-II diabetes |
| CN108948225A (en) * | 2018-10-09 | 2018-12-07 | 辽宁大学 | One kind having active Paecilomyces hepiali chen polysaccharide of anti diabetes and kidney disease and its preparation method and application |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20090120202A (en) * | 2008-05-19 | 2009-11-24 | 이수명 | Health food for the descent of hba1c |
| CN101991614A (en) * | 2010-09-13 | 2011-03-30 | 吴赣英 | Compound fermented cordyceps sinensis powder (paecilomyces hepiali Cs-4 bacterial powder) combined medicine and preparation thereof |
-
2015
- 2015-05-28 CN CN201510280983.3A patent/CN104906145B/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20090120202A (en) * | 2008-05-19 | 2009-11-24 | 이수명 | Health food for the descent of hba1c |
| CN101991614A (en) * | 2010-09-13 | 2011-03-30 | 吴赣英 | Compound fermented cordyceps sinensis powder (paecilomyces hepiali Cs-4 bacterial powder) combined medicine and preparation thereof |
Non-Patent Citations (2)
| Title |
|---|
| 向明 等: "人工虫草对链脲佐菌素所致小鼠1 型糖尿病的降糖作用及机制", 《中国医院药学杂志》 * |
| 汤静 等: "人工发酵虫草菌丝对链佐霉素致大鼠1型糖尿病的防治作用", 《中国药师》 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105853717A (en) * | 2016-04-05 | 2016-08-17 | 上海育生堂科技有限公司 | Chinese patent medicine for treating type-II diabetes |
| CN108948225A (en) * | 2018-10-09 | 2018-12-07 | 辽宁大学 | One kind having active Paecilomyces hepiali chen polysaccharide of anti diabetes and kidney disease and its preparation method and application |
Also Published As
| Publication number | Publication date |
|---|---|
| CN104906145B (en) | 2019-02-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1762967B (en) | Enoxolone derivative, preparation method and uses | |
| CN101856120A (en) | Health food for improving immunity of human body and preparation method thereof | |
| CN101347422B (en) | Uses of salvianolic acid A in preventing and/or treating diabetes and complication | |
| CN103405655B (en) | Chinese medicine composition of a kind of blood sugar lowering and preparation method thereof | |
| CN104257696A (en) | Yeast powder for reducing and stabilizing blood sugar as well as preparation method and application of yeast powder | |
| CN105341893A (en) | Composition for assisting in reducing blood glucose and application | |
| CN103417846B (en) | Chinese medicine composition of a kind of blood sugar lowering and preparation method thereof | |
| CN104906145B (en) | Medical application of the Paecilomyces hepiali chen mutagenic strain PH40 in treatment diabetes | |
| CN103989724B (en) | Blood sugar lowering heath food and preparation method thereof | |
| CN102860496B (en) | Oxidation-resisting health-care food for improving immunity and preparation method thereof | |
| CN108570116B (en) | Pleurotus citrinopileatus polysaccharide, preparation method and medical application in preventing and treating diabetes | |
| CN106924548A (en) | The medicine and preparation method of a kind of fatigue-relieving | |
| CN109248177B (en) | Preparation of crocodile amour effective component and application of crocodile amour effective component in oxidation resistance and hepatic fibrosis resistance | |
| CN103549008B (en) | Liquid dairy product rich in cellulose | |
| CN101264203B (en) | Chinese and western medicine composition for treating diabetes | |
| CN109223735B (en) | Use of active compounds isolated from secondary metabolites of aspergillus versicolor | |
| CN105168203A (en) | Application of schisandrin B in preparation of diabetes treatment drug | |
| CN101244041B (en) | Medicament for preventing and treating acute liver damnification and preparation thereof | |
| CN104784192A (en) | Application of clam meat oligosaccharide in preparation of hypoglycemic drugs and preparation method of clam meat oligosaccharide | |
| CN107661359A (en) | A kind of paecilomycerol pupa base cordyceps sinensis composition of strengthen immunity anti-aging and its application | |
| CN100363000C (en) | Chinese and western medicines composition contg. Avandia and its prepn. method | |
| CN100386089C (en) | Compound lentinan preparation and its preparing method | |
| CN104644768A (en) | Application of traditional Chinese medicine composition in preparation of medicine for treating kidney disease | |
| CN101721420A (en) | Antishock function of ginsenoside Re | |
| CN104644770A (en) | Application of traditional Chinese medicine composition in preparation of medicines for treating metabolic diseases |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| TA01 | Transfer of patent application right | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20170822 Address after: The 134003 Tonghua ducks in Jilin province Erdaojiang District West Village Hot Town Park Applicant after: Tonghua Shengyuan biological Polytron Technologies Inc Address before: 130011 Changchun Qianjin Street, Jilin, No. 2699 Applicant before: Jilin University |
|
| GR01 | Patent grant | ||
| GR01 | Patent grant |